Measles and Rubella vaccine

BIOLOGICAL4 trials

Sponsors

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz), GlaxoSmithKline, PATH, International Vaccine Institute

Conditions

HPV VaccineMalaria VaccinesMeaslesRubellaSalmonella Infections

Phase 2

Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella

CompletedNCT03148990

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)Measles, Rubella

Start: 2018-11-20End: 2020-08-12Updated: 2020-08-13

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

RecruitingNCT06213506

GlaxoSmithKlineSalmonella Infections

Start: 2024-01-15End: 2026-04-27Target: 516Updated: 2024-01-19

Infant Malaria Vaccine Schedule Optimization

RecruitingNCT06879327

PATHMalaria Vaccines

Start: 2025-05-30End: 2028-03-22Target: 1200Updated: 2025-08-03

Strengthening HPV Immunization Through EPI Leveraged Delivery

Not yet recruitingNCT07377656

International Vaccine InstituteHPV Vaccine

Start: 2026-01-16End: 2028-12-31Target: 115Updated: 2026-01-30